GlobeNewswire

Colchicine reduces the risk of COVID-19-related complications

Share

Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

MONTREAL, Jan. 23, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.

“Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19,” said Dr. Jean-Claude Tardif, Director of the MHI Research Center, Professor of Medicine at the Université de Montréal and Principal Investigator of the COLCORONA trial. “We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.”

Treating patients at risk of complications with colchicine as soon as the diagnosis of COVID-19 is confirmed by PCR reduces their risk of developing a severe form of the disease and, consequently, reduces the number of hospitalizations. Prescribing colchicine to patients could help alleviate the problems of hospital congestion and reduce healthcare costs here and around the world.

“Our innovative research program also proves that the Montreal Heart Institute can make rapid scientific breakthroughs in a way that is economically viable for patients by repurposing existing drugs,” continued Dr. Jean-Claude Tardif.

COLCORONA is a contact-less, randomized, double-blind, placebo-controlled clinical trial that took place at home. It has been conducted in Canada, the United States, Europe, South America and South Africa. It was designed to determine whether colchicine could reduce the risk of severe complications associated with COVID-19. COLCORONA was conducted among approximately 4,500 COVID-19 patients not hospitalized at the time of enrollment, with at least one risk factor for COVID-19 complications. This is the world’s largest study testing an orally administered drug in non-hospitalized patients with COVID-19.

COLCORONA was coordinated by the Montreal Heart Institute’s Montreal Health Innovations Coordinating Center (MHICC), and funded by the Government of Quebec, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), Montreal philanthropist Sophie Desmarais, and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard. CGI, Dacima and Pharmascience of Montreal were also collaborators in the trial.

The Montreal Heart Institute and its global partners would like to warmly thank the participants and researchers for their collaboration in the COLCORONA clinical trial.

For more information, visit colcorona.net.

About the Montreal Heart Institute 
Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the Université de Montréal and has more than 2,000 employees, including 245 doctors and more than 85 researchers. icm-mhi.org

About the Montreal Health Innovations Coordinating Center (MHICC) 
The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4,500 clinical sites in more than 35 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing. mhicc.org

About Pharmascience
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private pharmaceutical company with deep roots in Canada, and whose global reach spans across more than 60 countries. Ranked 47th among the top 100 Canadian investors in Research and Development (R&D), thanks to $49,5 million investment in 2018, Pharmascience Inc. is one of the largest manufacturer of generic drugs in the country. pharmascience.com

About CGI
Founded in 1976, CGI is one of the world’s largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. cgi.com/canada

About Dacima
Founded in 2006, Dacima Software Inc. is a leading innovator in Electronic Data Capture (EDC) software for clinical research. Dacima’s EDC software, Dacima Clinical Suite, is a fully feature EDC software application with integrated modules for patient randomization (IWRS), supply management, ePRO, eDiary, medical coding and eConsent. Dacima’s flexible and highly configurable EDC platforms allow for the design of all types of study designs including clinical trials, patient registries, observational studies and web surveys through an intuitive user-friendly web interface. dacimasoftware.com

About the COVID-19 Therapeutics Accelerator
The Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with support from public and philanthropic donors to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments. Its partners are committed to equitable access, including making products available and affordable in low-resource settings. https://www.therapeuticsaccelerator.org/

Media Contacts:
Camille Turbide
Camille.turbide@gmail.com
Canada : + 514 755-5354
Europe : +33 07 85 95 11 29

United States
Christy Maginn
christymmaginn@msn.com
+ 1 703 297-7194



About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States4.3.2021 22:00:00 CETPress release

► Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development ► Breakthrough Therapy Designation granted to lanifibranor in NASH by the U.S. Food and Drug Administration (FDA) ► Finalization of Phase III clinical trial design with lanifibranor in NASH following end-of-phase II meeting with the FDA and receipt of Scientific Advice letter from the European Medicines Agency (EMA) ► Expansion into the United States with appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer and opening of U.S. subsidiary ► Announcement of timeline for Phase III clinical trial evaluating lanifibranor in NASH ► Confirmation by the FDA that the toxicology package regarding lanifibranor is complete and acceptable to support the filing of a New Drug Application (NDA) for the treatment of NASH and improvement of liver fibrosis ► Completion of World Health Organization’s (WHO) International No

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report4.3.2021 22:00:00 CETPress release

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report Nokia Corporation Stock Exchange Release March 4, 2021 at 23:00 EET Nokia has filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission and published its Nokia in 2020 Annual Report. Espoo, Finland – Nokia has today filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission. Additionally, Nokia has published its Nokia in 2020 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2020. The Annual Report on Form 20-F and Nokia in 2020 Annual Report will be available in PDF format at www.nokia.com/about-us/investors/reports-filings, along with Nokia’s past quarterly and annual financial reports. Shareholders may request a hard copy of the reports free of charge through Nok

Appellate Court Hands Momentous Victory to TriMax Over Wickfire4.3.2021 21:35:30 CETPress release

The Fifth Circuit Court of Appeals issued a decisive ruling that TriMax Media committed no legal violations against Wickfire, L.L.C., while recognizing a jury’s finding that Wickfire intentionally interfered with TriMax’s business. DALLAS, March 04, 2021 (GLOBE NEWSWIRE) -- After seven years of litigation, TriMax has triumphed over Wickfire. On February 26, 2021, an Appellate Court issued a paramount ruling that Wickfire lacked any evidence to support its claims against TriMax. The decision was made in the United States Court of Appeals for the Fifth Circuit, Case Number 17-3043040. The Appellate Court’s ruling reversed all monetary damages previously awarded to Wickfire. The lawsuit, originally before the Western District of Texas, Case No. 14-CV-34, centered around Google AdWords Auctions, an online-auction platform where companies like TriMax and Wickfire compete for advertising space. Wickfire asserted innumerable claims against TriMax, but as to each one, Wickfire ultimately faile

Informa Markets Drives Economic Recovery with Safe and Successful Return to the Show Floor4.3.2021 20:52:58 CETPress release

Informa Markets makes a customer-driven return to live events, driving economic recovery, connection and innovation through a collaborative and foundational approach to safety ORLANDO, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- As industries and economies around the world look for opportunities to rebuild business in the wake of the COVID-19 pandemic, Informa Markets, a global organizer who creates platforms for a wide range of industries to trade, connect and grow, launched MAGIC Pop-Up Orlando from February 9-11 at the Orange County Convention Center. The ‘Pop-Up’, a smaller scale regional version of their keystone fashion event which typically takes place twice-yearly in Las Vegas, Nevada was a comprehensive ‘one-stop-shop’ opportunity for various segments of the fashion industry, one of the many industries hit hard by the pandemic’s devastating economic impact, to discover new brands, safely network with like-minded retailers, and generate much-needed revenue. Informa Markets Fashion

CoinShares announces outcome of offering in connection with its intended listing on Nasdaq First North Growth Market4.3.2021 20:30:00 CETPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Saint Helier, JERSEY, 4 March, 2021 The subscription period for shares in the initial public offering (the “Offering”) from CoinShares International Limited (“CoinShares” or the “Company”) ended Tuesday, 2 March, 2021. The outcome of the Offering shows that the Offering was subscribed to 447% and that the Company will receive proceeds of SEK 151.1 million before issue costs. The Offering of SEK 151.1 million was covered by subscription commitments of SEK 125.5 million, corresponding to 83% of the total